Hikma Pharmaceuticals (HIK) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Jun 2025 03:33 PM
RNS
Director/PDMR Shareholding
05 Jun 2025 02:05 PM
RNS
Director/PDMR Shareholding
03 Jun 2025 01:02 PM
RNS
Director/PDMR Shareholding
29 May 2025 07:00 AM
RNS
Fitch upgrades Hikma to ‘BBB’
20 May 2025 02:49 PM
RNS
Director/PDMR Shareholding
15 May 2025 12:00 PM
RNS
Medium-term Group guidance ahead of US site visit
08 May 2025 04:35 PM
RNS
Director/PDMR Shareholding
08 May 2025 10:48 AM
RNS
S&P upgrades Hikma to ‘BBB’
08 May 2025 08:21 AM
RNS
Settlement agreement for Xyrem® US lawsuits
30 Apr 2025 01:21 PM
RNS
Director/PDMR Shareholding
24 Apr 2025 03:55 PM
RNS
Result of AGM
24 Apr 2025 07:00 AM
RNS
Trading Statement
10 Apr 2025 02:36 PM
RNS
Director/PDMR Shareholding
08 Apr 2025 01:47 PM
RNS
Director/PDMR Shareholding
01 Apr 2025 09:30 AM
RNS
Block listing Interim Review
19 Mar 2025 10:10 AM
RNS
Annual Financial Report and Notice of AGM
04 Mar 2025 11:16 AM
RNS
Director/PDMR Shareholding
26 Feb 2025 07:00 AM
RNS
Final Results
10 Feb 2025 08:09 AM
RNS
Notice of Results
23 Dec 2024 09:46 AM
RNS
Director/PDMR Shareholding
07 Nov 2024 03:30 PM
RNS
Outcome of Audit Tender Process
07 Nov 2024 07:00 AM
RNS
Trading Statement
24 Oct 2024 07:00 AM
RNS
2024 Annual General Meeting Update Statement
01 Oct 2024 09:45 AM
RNS
Block listing Interim Review
24 Sep 2024 10:09 AM
RNS
Director/PDMR Shareholding
10 Sep 2024 07:00 AM
RNS
Hikma completes Xellia acquisition
13 Aug 2024 09:39 AM
RNS
Director/PDMR Shareholding
08 Aug 2024 07:00 AM
RNS
Half-year Report
29 Jul 2024 04:08 PM
RNS
Director Declaration
15 Jul 2024 07:00 AM
RNS
Notice of Results
01 Jul 2024 02:47 PM
RNS
Total Voting Rights
27 Jun 2024 01:47 PM
RNS
Director Declaration
17 Jun 2024 07:00 AM
RNS
Hikma acquires Xellia’s assets
05 Jun 2024 02:53 PM
RNS
Director/PDMR Shareholding
09 May 2024 09:49 AM
RNS
Director/PDMR Shareholding
25 Apr 2024 02:28 PM
RNS
Result of AGM
25 Apr 2024 07:00 AM
RNS
Trading Statement
17 Apr 2024 10:42 AM
RNS
Director/PDMR Shareholding
15 Apr 2024 04:43 PM
RNS
Hikma appoints new President of Generics business
11 Apr 2024 10:58 AM
RNS
Director/PDMR Shareholding
02 Apr 2024 09:50 AM
RNS
Block listing Interim Review
02 Apr 2024 09:50 AM
RNS
Block listing Interim Review
22 Mar 2024 09:21 AM
RNS
Annual Financial Report and Notice of AGM
13 Mar 2024 09:42 AM
RNS
Director/PDMR Shareholding
07 Mar 2024 01:52 PM
RNS
Director/PDMR Shareholding
01 Mar 2024 10:17 AM
RNS
Total Voting Rights
22 Feb 2024 07:00 AM
RNS
Final Results
05 Feb 2024 08:46 AM
RNS
Notice of Results
01 Feb 2024 06:22 PM
RNS
Agreement in Principle for US Opioid Settlement
01 Feb 2024 12:08 PM
RNS
Total Voting Rights

Hikma Pharmaceuticals is a British multinational pharmaceutical company, founded in 1978, that develops, manufactures, and markets a wide range of generic, branded, and in-licensed pharmaceutical products, with a focus on making high-quality medicines accessible.

Hikma share price launched at 281p in 2005.

 

UK 100

Latest directors dealings